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Summary
 
Using lymphocyte function-associated antigen (LFA)-1
 
2
 
/
 
2
 
 
 
mice, we have examined the role of
LFA-1 and other integrins in the recirculation of lymphocytes. LFA-1 has a key role in migra-
tion to peripheral lymph nodes (pLNs), and influences migration into other LNs. Second, the
 
a
 
4 integrins, 
 
a
 
4
 
b
 
7 and 
 
a
 
4
 
b
 
1, have a hitherto unrecognized ability to compensate for the lack
of LFA-1 in migration to pLNs. These findings are confirmed using normal mice and blocking
LFA-1 and 
 
a
 
4 monoclonal antibodies. Unexpectedly, vascular cell adhesion molecule (VCAM)-1,
which is essential in inflammatory responses, serves as the ligand for the 
 
a
 
4 integrins on pLN
high endothelial venules. VCAM-1 also participates in trafficking into mesenteric LNs and
Peyer’s patch nodes where mucosal addressin cell adhesion molecule 1 (MAdCAM-1), the
 
a
 
4
 
b
 
7-specific ligand, dominates. Both 
 
a
 
4
 
b
 
1, interacting with ligand VCAM-1, and also LFA-1
participate in substantial lymphocyte recirculation through bone marrow. These observations
suggest that organ-specific adhesion receptor usage in mature lymphocyte recirculation is not as
rigidly adhered to as previously considered, and that the same basic sets of adhesion receptors
are used in both lymphocyte homing and inflammatory responses.
Key words: adhesion • integrin • homing • bone marrow • lymphocyte
 
T
 
he integrin LFA-1 (CD11a/CD18), which belongs to
the 
 
b
 
2 family of integrin receptors, is expressed by all
leukocytes and has a central role in the functions of these
cells. When leukocytes respond to inflammatory signals,
LFA-1 acts together with other adhesion receptors to direct
the cells into injured tissues (see references 1–4). Thus, the
selectin adhesion receptors allow transient leukocyte contact
with stimulated endothelium, causing a rolling movement
which is further arrested by the action of the 
 
a
 
4 integrins.
This stage is followed by a signaling event that activates
LFA-1 to promote firm adhesion of the leukocytes and
their migration across the endothelium towards the area of
injury.
In contrast, mature lymphocytes, but not myeloid cells,
circulate continually through secondary lymphoid tissue
of the peripheral lymph nodes (pLNs),
 
1
 
 mesenteric LNs
(mLNs), and Peyer’s patches (PPs), thereby increasing the
opportunity for an encounter with antigen. To migrate
across the specialized high endothelial venules (HEVs) of
these LNs, lymphocytes have been proposed to use organ-
specific sets of adhesion receptors (4, 5). Migration into
mucosal tissue such as PPs is greatly dependent on the 
 
a
 
4
integrin, 
 
a
 
4
 
b
 
7, which has no apparent role in homing to
the pLNs (6, 7). On the other hand, homing of naive lym-
phocytes to pLNs has been considered to be dependent
 
upon L-selectin (CD62L) but not to involve the 
 
a
 
4 inte-
grins (8, 9). However, parallels are emerging between the
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Abbreviations used in this paper:
 
 CT, CellTracker™; ES, embryonic stem;
HEV, high endothelial venule; HUVEC, human umbilical vein endothe-
lial cell; ICAM, intercellular adhesion molecule; MAdCAM-1, mucosal
addressin cell adhesion molecule 1; pLN, peripheral lymph node; PNAd,
peripheral node addressin; PP, Peyer’s patch; VCAM, vascular cell adhe-
sion molecule. 
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Role of LFA-1 and 
 
a
 
4 Integrins in Lymphocyte Recirculation
 
processes of lymphocyte recirculation and the response to in-
flammatory signals. LFA-1 influences migration into mucosal
tissue as well as the pLNs (10), and there is now evidence
that recirculating lymphocytes also undergo an activation
step when they contact the HEVs. LFA-1 can be activated
by signals arising from the binding of lymphocyte L-selectin
to HEV ligand, GlyCAM-1 (11). HEV-expressed chemo-
kines B lymphocyte chemoattractant (BLC) and secondary
lymphoid tissue chemokine (SLC) cause adhesion of naive
B cells (12) and T cells (13), respectively, and SLC has been
demonstrated to activate LFA-1.
Ligands for most of the lymphocyte adhesion receptors
have been identified on the HEVs. L-selectin recognizes
peripheral node addressin (PNAd), a group of fucosylated
and sialylated LewisX-expressing proteins on pLN HEVs
(see reference 14). LFA-1 functions through recognition of
its ligands intercellular adhesion molecule (ICAM)-1 or
ICAM-2 (see reference 15). The 
 
a
 
4
 
b
 
7 integrin recognizes
MAdCAM-1, which is expressed on HEVs in PPs and
mLNs (16, 17), and VCAM-1 and fibronectin. The alter-
native 
 
a
 
4 integrin, 
 
a
 
4
 
b
 
1, which has a major role in in-
flammation (18–20), also recognizes ligands VCAM-1 and
fibronectin. VCAM-1 is expressed by endothelia under in-
flammatory conditions (21, 22) and is thought to be absent
on normal LN endothelium (22, 23). Fibronectin is gen-
erally associated only with the subendothelial matrix,
but there is a report that a spliced variant is expressed in
rheumatoid arthritis tissue (24). Thus, the ligand binding
activities of the two 
 
a
 
4 integrins are distinctive, in that
MAdCAM-1 is involved in 
 
a
 
4
 
b
 
7-mediated naive lympho-
cyte homing to mucosal sites whereas VCAM-1 primarily
serves as the ligand for 
 
a
 
4
 
b
 
1 at inflammatory sites.
Recently, two studies using LFA-1–deficient mice have
confirmed many of the previous assignments of LFA-1
function, for example, in assays for T cell function such as
MLR and delayed-type hypersensitivity responses (25, 26).
In this study, we have used LFA-1
 
2
 
/
 
2
 
 
 
mice to reexamine
the role of LFA-1 in the recirculation of lymphocytes and
to investigate alternative mechanisms used in its absence.
We confirm an important role for LFA-1 in LN localiza-
tion, identify an unexpected role for 
 
a
 
4 integrins, 
 
a
 
4
 
b
 
7
and 
 
a
 
4
 
b
 
1, in pLN homing that is mediated by HEV-
expressed VCAM-1, and finally demonstrate that 
 
a
 
4
 
b
 
1/
VCAM-1 together with LFA-1 is involved in migration of
lymphocytes to bone marrow.
 
Materials and Methods
 
Generation of LFA-1 Mutant Mice.
 
A 7-kb PCR product am-
plified from murine 129/Sv genomic DNA and containing exon 2
of the
 
 Lfa-1
 
 gene was subcloned into pSP72. A selection cassette
containing stop codons in all three frames, an independent ribo-
somal entry sequence (IRES) followed by the LacZ gene with an
SV40 polyadenylation signal, and a neomycin phosphotransferase
gene was introduced into exon 2. Culture and transfection of
GK129 embryonic stem (ES) cells was done as described previ-
ously (27). EcoRI-digested ES cell DNA was analyzed by South-
ern blot analysis using probe A, and homologous recombination
 
was confirmed using probe B (see Fig. 1 a). Blastocyst injection
and breeding have been described previously (27). Mice were
genotyped from EcoRI-digested tail DNA by Southern blot (data
not shown) or PCR (Fig. 1 b). A multiplex PCR using primers
on either side of the selection cassette and one within the neo-
mycin resistance gene yielded fragments of 90 bp (wild-type)
and 660 bp (LFA-1–deficient), respectively.
 
Animal Husbandry.
 
All mice were kept under specific patho-
gen–free conditions and in accordance with United Kingdom
Home Office regulations. The mice were monitored on a six-
monthly basis for a wide selection of parasites, bacteria, and fungi
and were regularly found to be pathogen free. LN sections from
sentinel mice belonging to litters used in the reported experi-
ments were inspected for the presence of germinal centers by he-
matoxylin and eosin staining and for positive MAdCAM-1 stain-
ing in pLNs (28). These latter indicators of an inflammatory
response were routinely negative for mice housed in London and
Hamburg.
 
mAbs and Other Reagents.
 
The following purified rat mAbs
were used in this study: LFA-1 
 
a
 
 subunit mAbs H35.89.9 (IgG2b)
and H68 (IgG2a), both obtained from Dr. Michel Pierres (Centre
d’Immunologie, INSERM-CNRS de Marseille-Luminy, Marseille,
France); 
 
a
 
4 subunit mAb PS/2 (IgG2b); anti–VCAM-1 mAb
MK2.7 (IgG1); anti–MAdCAM-1 mAb MECA-367 (IgG2a),
obtained from American Type Culture Collection; anti-PNAd
mAb MECA-79 (IgM; obtained from Drs. Mark Singer and
Steve Rosen, University of California, San Francisco, CA);
MECA-325 (IgG1), obtained from Dr. A. Duijvestijn (University
of Limburg, Maastricht, Netherlands); CD54 mAb YN1/1.7
(IgG2a; obtained from Dr. Fumio Takei, Terry Fox Laboratory,
BC Cancer Research Centre, Vancouver, Canada); CD4, CD8,
and B220 mAbs (PharMingen); and control rat IgG1 mAb PyLT-1
(IgG1; Imperial Cancer Research Fund) and control null rat IgG1
and IgG2a mAbs (PharMingen). Secondary detection antibodies
were FITC-conjugated goat anti–rat Ig (Jackson Immuno-
Research Laboratories) and biotinylated rabbit anti–rat Ig (Vector
Laboratories). Fab fragments were prepared by papain digestion
using either the ImmunoPure
 
®
 
 Fab kit (Pierce Chemical Co.)
or HPLC to remove any residual intact IgG (7).
 
Preparation of Cells for Flow Cytometry.
 
Single cell suspensions
from 8–12-wk-old mice were prepared by mincing or rubbing
between glass slides with frequent rinsing with 5% FCS/RPMI or
0.2% BSA/PBS. Bone marrow cells were harvested by flushing
with 5% FCS/RPMI via cut ends of tibias and femurs, followed
by disaggregation and filtering through nylon gauze. Cells were
washed and incubated at 5 
 
3 
 
10
 
6
 
 cells/ml with specific primary
mAbs, then FITC-conjugated goat anti–rat Ig (1:200; Jackson
ImmunoResearch Laboratories) at 4
 
8
 
C for 30 min. Cells were
fixed in 1% HCHO/PBS before analysis on a FACScan™ instru-
ment (Becton Dickinson).
 
In Vivo Homing Experiments Using CellTracker™ Fluorescent
Dye–labeled Lymphocytes.
 
Lymphocytes from pLNs and mLNs of
LFA-1
 
1
 
/
 
1
 
 
 
and LFA-1
 
2
 
/
 
2
 
 mice were prepared and adjusted to 5 
 
3
 
10
 
6
 
 cells/ml in 5% FCS/RPMI for labeling as described (29).
LFA-1
 
1
 
/
 
1
 
 
 
lymphocytes were incubated with 0.2 mM CellTracker™
(CT) Green 5-chloromethylfluorescein diacetate (CMFDA; Molec-
ular Probes) and LFA-1
 
2
 
/
 
2
 
 lymphocytes with 5 mM CT Orange
5-chloromethyl tetramethylrhodamine (CMTMR) at 37
 
8
 
C for
45 min. The two cell preparations were washed and counted,
then mixed together to achieve a 1:1 ratio of differentially labeled
LFA-1
 
1
 
/
 
1
 
 
 
and LFA-1
 
2
 
/
 
2
 
 lymphocytes for injection into recipient
8–12-wk-old C57BL/6 mice for a period of 1 h. A correction
factor was applied to the subsequent data if the lymphocyte ratio 
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was not precisely 1:1. Reversing the CT dyes had no effect on
results. The lymphocytes were frequently tested for activation
status before and after the labeling procedure by measuring the
level of L-selectin that can be enzymatically cleaved after an acti-
vating stimulus (30). In general, a total of 2 
 
3
 
 10
 
7
 
 cells in a vol-
ume of 200 
 
m
 
l was injected per tail vein. In experiments involv-
ing antibody blocking, the cells and mAbs were coinjected. Fab
fragments were used in amounts of 250–400 
 
m
 
g per mouse. Irrel-
evant control Fab fragments were without effect.
 
In Vivo Homing Experiments Using 
 
51
 
Cr-labeled Lymphocytes.
 
Lymphocytes obtained as above were labeled with 20 
 
m
 
Ci 
 
51
 
Cr/ml
as described previously (29), and dead cells removed by centrif-
ugation on a 17% Nycodenz cushion (Nycomed). 5 
 
3 
 
10
 
6
 
lymphocytes in 200 
 
m
 
l were injected into the tail vein of recipi-
ent 8–12-wk-old C57BL/6 mice. mAbs were coinjected as Fab
fragments and at 300 
 
m
 
g/200 
 
m
 
l. Sample groups of four mice
were used in each condition. The mice were killed after 1 h, and
the distribution of radioactivity was determined for the different
organs and for the residual body mass. PBLs were calculated for a
blood volume of 1.5 ml.
 
Labeling, Injection, and Detection of Donor Cells in the Host pLNs.
 
LN cells were labeled by dissolving 1 mg digoxigenin in 0.5 ml
DMSO and incubating the lymphocytes for 15 min at a final
concentration of 5 
 
3
 
 10
 
7
 
 cells/ml with 60 
 
m
 
g digoxigenin. After
washing, 0.8 
 
3 
 
10
 
7
 
 cells were injected intravenously, and pLNs
were removed 30 min later and frozen in liquid nitrogen. To lo-
calize the donor cells in the HEVs, two antigens were revealed
simultaneously as described (31). In brief, cryostat sections were
incubated with the anti-HEV mAb MECA-325, which was re-
vealed by the alkaline phosphatase anti-alkaline phosphatase
(APAAP) technique (blue [31]). The donor cells were identified
by a peroxidase-conjugated antidigoxigenin antibody (brown) as
described previously (31). The area of the HEVs (excluding the
lumen) together with the area within 4-cell diameters surround-
ing the vessel was then determined (31), and the number of in-
jected cells adhering to and within the endothelium, and within
the tissue was analyzed.
 
Immunohistochemistry.
 
Sections of 6 
 
m
 
m were cut from snap-
frozen tissues of pLN, mLN, and PP and placed on silane-coated
slides which were fixed in acetone for 10 min and allowed to air
dry. Slides were washed in standard Tris-buffered saline (TBS),
pH 7.6, and primary mAb was added for 1 h at room tempera-
ture. mAbs were used at optimal dilution: 10 
 
m
 
g/ml for anti–
VCAM-1 mAb MK2.7 (IgG1) and IgG1 isotype control mAb
PyLT-1, MECA-79 at 4 
 
m
 
g/ml, and MECA-367 as tissue culture
supernatant. Sections were also tested with null IgG1 and IgG2a
mAbs (PharMingen; data not shown). Biotinylated rabbit anti–rat
Ig (1:100; Vector Laboratories) was added for 35 min. A tertiary
stage was carried out using the StreptABComplex/HRP kit fol-
lowing the manufacturer’s instructions (K377; Dako), and the
slides were incubated again for 35 min before exposure to 1 mg/ml
3,3
 
9
 
diaminobenzidine.
 
Results
 
Disruption of the Lfa-1 Gene. Lfa-1
 
, the gene for the
LFA-1 
 
a
 
 subunit, was mutated in ES cells using a replace-
ment-type targeting vector and the strategy shown in Fig. 1 a.
G418-resistant colonies were identified by Southern blot
analysis of EcoR1-digested ES cell genomic DNA using
the probe shown in Fig. 1 a. Of 400 G418-resistant ES cell
colonies, 10 correctly targeted colonies were identified.
Three different homologously targeted ES cell clones were
injected into C57BL/6 blastocysts, and all of them were
transmitted through the germline. Southern blot analysis of
mouse tail DNA enabled identification of LFA-1 wild-type
(
 
1
 
/
 
1
 
), heterozygous (
 
1
 
/
 
2
 
), and gene-deleted status (
 
2
 
/2)
(data not shown). This was confirmed by PCR analysis
(Fig. 1 b).
Absence of LFA-1 Expression and Function In Vitro. To
establish that the capacity for LFA-1 synthesis had been
completely ablated, leukocyte populations were examined
for LFA-1 expression and function. Thymocytes from
LFA-12/2 mice were compared with LFA-11/1 littermates
and shown to be devoid of LFA-1 expression (Fig. 1 c).
The lack of LFA-1 surface expression was also demon-
strated for leukocytes from other lymphoid tissue, includ-
ing pLN, mLN, PP, spleen, bone marrow, and blood (data
not shown). To test for absence of LFA-1 function, control
Figure 1. Generation of LFA-1–deficient mice, showing (a) the design of the
targeting construct and the site of insertion of the selectable cassette within exon
2 of the LFA-1a gene; and (b) PCR analysis of the wild-type, heterozygous, and
homozygous LFA-1 mutant mice genotypes (B, BamH1; E, EcoR1; K, Kpn1;
N, Not1; S, Sac1). (c) Flow cytometric analysis of thymocytes from wild-type
and homozygous LFA-1 mutant mice stained with anti–LFA-1 mAb H68 (solid
line) or no primary antibody (dotted line). The mean fluorescence intensities are
indicated.1470 Role of LFA-1 and a4 Integrins in Lymphocyte Recirculation
phorbol ester–treated LFA-11/1 thymocytes were adhered
to murine ICAM-1–transfected COS-7 cells, and this ad-
hesion could be blocked with anti–LFA-1 mAb H68 (data
not shown). In contrast, no adhesion was evident with
LFA-12/2 thymocytes. Therefore, testing for both expres-
sion and function of the LFA-1 receptor provided further
proof that the LFA-12/2 mice were totally deficient in this
b2 integrin.
Status of Secondary Lymphoid Tissue. Analysis of LFA-12/2
compared with LFA-11/1 mice revealed an increase in spleen
size and a decrease in size of the pLNs, as observed previ-
ously (25). For 30-g male mice (n 5 29), the LFA-12/2
spleens were 1.7 times larger than those of LFA-11/1 mice
(182.0 6 56.4 compared with 107.8 6 30.0 mg). For 25-g
female mice (n 5 37), the same comparison yielded a
1.2-fold increase in weight (137.6 6 33.0 compared with
118.5 6 42.3 mg). Second, the pLNs from LFA-12/2 mice
were smaller than those from LFA-11/1 mice, with an av-
erage decreased lymphocyte number for LFA-12/2 mice of
z30% that of the LFA-11/1 littermates (3.54 6 0.74 3
106 compared with 12.15 6 2.90 3 106; n 5 9).
To discover whether alteration had occurred in lympho-
cyte numbers in general or in a particular subtype, we next
analyzed CD4 and CD8 T cell subsets and used mAb B220
to detect B cells. In the pLNs, substantial loss in numbers of
CD4 and CD8 T cells as well as a deficiency in B cells was
observed (Fig. 2). Furthermore, there was no difference in
naive versus memory phenotype in LFA-12/2 and LFA-11/1
mice as indicated by expression levels of L-selectin, CD44,
and CD45RB antigens (data not shown). In the other LNs,
wild-type and LFA-1–deficient mice were similar in terms
of lymphocyte numbers and subsets, as was expected from
the fact that these LNs were comparable in size between
the two types of mice. In spleen, there was a significant in-
crease in CD4 T cells and CD8 cells (Fig. 2).
Lymphocyte Homing in LFA-1–deficient Mice. To gain
further information about the diminished cellularity of the
pLNs and to investigate trafficking capabilities of LFA-
1–deficient lymphocytes, short-term migration studies were
performed. The approach taken was to label LFA-12/2 and
LFA-11/1 lymphocytes with two distinguishable CT orange
and green fluorescent dyes and inject equivalent numbers
into the tail vein of C57BL/6 recipients. This allowed di-
rect comparison of the homing activity of the lymphocytes
within each LN setting (29). An example of the method-
ology is illustrated in Fig. 3 a. When the pLN lymphocytes
were examined for proportions of CT orange to green after
1 h of homing, it was observed that z13% of LFA-12/2
cells compared with LFA-11/1 cells had migrated into the
pLNs (Fig. 3 a). We then examined the relative ability of
LFA-12/2 cells to gain entry into other secondary lym-
phoid tissues (Fig. 3 b). When compared with LFA-11/1,
the LFA-12/2 cells were most poorly represented in pLNs
(0.21 6 0.01), followed by mLNs (0.51 6 0.02) and PPs
(0.68 6 0.03). In contrast, there was a marked increase in
the LFA-12/2 cells in the spleen (1.29 6 0.04) which is
likely due to redistribution of lymphocytes from LN to
spleen. These findings on the effect of LFA-1 absence on
the trafficking of lymphocytes were confirmed using the
technique of tracking 51Cr-labeled lymphocytes to compare
homing in LFA-12/2 and LFA-11/1 mice (data not shown).
When CD4, CD8, and B2201 lymphocyte subsets were
analyzed separately, the ratio of migrated to injected lym-
phocytes was identical among the subsets whether derived
from wild-type or LFA-12/2 mice, indicating that the lack
of LFA-1 caused equal difficulty for all types of lympho-
cytes to gain entry into the LNs (data not shown).
LFA-12/2 Lymphocytes Show Limited Adhesion to LN
HEVs. The above findings showed that LFA-12/2 cells
migrated less effectively, particularly to the pLNs, within
the 1-h period but did not reveal the stage at which the
lack of LFA-1 had its effect. To discover where LFA-1 de-
ficiency caused difficulty, we turned to histochemistry and
examined pLN tissue sections from mice injected with
Figure 2. A comparison of lymphocyte
numbers in the pLNs and spleens of wild-
type and LFA-1–deficient mutant mice. In
the pLNs, decreased numbers of CD4 (P ,
0.001), CD8 (P , 0.001) T cells and B cells
are present in LFA-12/2  compared with
wild-type mice. The spleens of these mice
show increased numbers of CD4 (P ,
0.0001) and CD8 (P , 0.02) cells. White
bars, LFA-11/1; gray bars, LFA-12/2. Statis-
tical analysis was performed using the t test.1471 Berlin-Rufenach et al.
LFA-12/2 and LFA-11/1 lymphocytes for 30 min. As
shown in Fig. 4, the LFA-1–deficient lymphocytes bound
less well to HEVs than the LFA-1-expressing lymphocytes.
The total numbers of lymphocytes at the HEV level and sur-
rounding 4-cell diameters were 285 6 70 cells/mm2 for
LFA-11/1 (Fig. 4, a and b) and 85 6 10 cells/mm2 for LFA-
12/2 lymphocytes (Fig. 4, c and d) (n 5 3). These data sug-
gest that loss of LFA-1 expression reduces lymphocyte ad-
herence to and transmigration across HEVs by 70%, thereby
causing substantially diminished recruitment into pLNs.
When the cells were divided between those adhering to and
within the HEVs and those found within 4-cell diameters
beyond HEVs, the following proportions were observed: for
LFA-11/1 lymphocytes, 73 6 7 and 276 2%; for LFA-12/2
lymphocytes, 78 6 1 and 22 6 1%, respectively. These data
suggest that the major block is at the level of the HEVs. If
the deficiency had been acting selectively at the level of the
transmigration step, a larger accumulation of lymphocytes at
the HEV level would have been expected.
A General Role for a4 Integrins and LFA-1 in LN Homing.
Although LFA-1 was obviously playing a critical role at the
HEV level, a proportion of lymphocytes remained capable
of migrating into lymphoid tissue (Fig. 3 b, and Fig. 4). Of
other adhesion receptors that might substitute for LFA-1,
the a4 integrins were attractive candidates, as they were active
in migration in other situations. In the next series of experi-
ments, the migratory behavior of CT-labeled LFA-12/2 and
LFA-11/1 cells was compared in host animals simulta-
neously injected with Fab fragments of a4 mAb or a4b7-
specific mAb. The a4 mAb completely prevented the mi-
gration of the residual numbers of LFA-12/2 lymphocytes
homing to pLNs, mLNs, and PPs (Fig. 5). In addition, the
a4b7-specific mAb blocked lymphocyte entry into pLNs
to z22% and completely prevented migration into mLNs
and PPs. There was no significant effect of a4 or a4b7
mAbs on migration into spleen.
These results were duplicated in a 51Cr lymphocyte la-
beling experiment in which a4 mAb abolished all entry
into the pLNs, mLNs, and PPs of LFA-12/2 lymphocytes
(data not shown). The a4b7 mAb blocked entry into
mLNs and PPs and inhibited entry into pLNs to z35%
(data not shown). It was possible that the a4-dependent
LFA-12/2 cells migrating into pLNs were a specific subset
of lymphocytes expanded in the LFA-1–deficient environ-
ment. However, phenotyping of these cells using a third
fluorescent tag of Tricolor-conjugated anti–rat Ig showed
the migrated LFA-12/2 and LFA-11/1 lymphocytes to have
identical phenotypic profiles with regard to their levels of
a4 and a4b7 integrins and L-selectin (data not shown).
The suggestion that a4 integrins, a4b7 acting together
with a4b1, have a role in migration to the pLNs has not
previously been recognized. To further confirm the find-
ings and to gain information about tissues other than second-
ary LNs, 51Cr-labeled lymphocytes from normal BALB/c
mice were coinjected with 300 mg of Fab fragments from
either a4 mAb, LFA-1 mAb, or both into host BALB/c
mice. The findings with the single mAbs were as reported
previously (7, 10; Fig. 6), but the combination of a4 and
LFA-1 mAbs totally prevented migration into pLNs as well
as mLNs and PPs (Fig. 6). There was also an appreciable
decrease in migration into intestinal tissue and into the
“body” (see below). This mAb blockade provoked an in-
crease in circulating blood cells as well as an increase in mi-
gration into the spleen. Put together, these observations
provide evidence that the a4 integrins operating together
with LFA-1 have an essential role in migration to pLNs, as
found previously for other secondary LNs.
Ligands for a4 Integrins on LN HEVs. The identification
of the ligand(s) recognized by the a4 integrins, particularly
in pLNs, was next explored. Using a MAdCAM-1–specific
mAb, homing to both PPs and mLNs was substantially pre-
vented, as described previously (16, 17; Fig. 5). However,
Figure 3. Differential rates of homing of CT-labeled lymphocytes from
wild-type and LFA-12/2 mice. (a) Two-color FACS® analysis of the cell
mixture of LFA-12/2 and LFA-11/1 cells injected intravenously into a wild-
type C57BL/6 mouse (left) and the fluorescent cells recovered from the
pLNs after a 1-h homing period (right). For details, see Materials and Meth-
ods. (b) Homing experiments show that within 1 h, LFA-12/2 lymphocytes
migrate into pLNs, mLNs, and PPs with 21, 51, and 68% of the efficiency of
LFA-11/1 lymphocytes, respectively. Conversely, LFA-1–deficient lympho-
cytes occur in larger numbers in the spleen than do wild-type cells (ratio of
1.29). These data are averaged from 10–12 experiments. In all cases, the
mean ratios are significantly different from 1.0 (P , 0.05) as assessed by t test.1472 Role of LFA-1 and a4 Integrins in Lymphocyte Recirculation
Figure 4. Tissue sections of
pLNs showing the distribution
of injected digoxigenin-labeled
lymphocytes from LFA-11/1 or
LFA-12/2 animals in relation to
HEVs. (a) Overview of a
C57BL/6 pLN 30 min after in-
jection of LFA-11/1  lympho-
cytes showing HEVs labeled
with mAb MECA-325 (blue)
and injected cells (brown). (b)
Higher magnification shows in-
jected LFA-11/1  cells (brown)
within and around the HEVs
(blue). They are either adhered
to or within the endothelium
(black arrowheads), or are al-
ready within the tissue (black
arrows). (c) Overview of a pLN
after injection of LFA-12/2
lymphocytes. (d) Higher magni-
fication shows only one injected
LFA-12/2 cell can be seen
within the HEV (black arrow-
head), and the number of mi-
grated lymphocytes within the
node is markedly reduced. Orig-
inal magnifications: a and c,
360; b and d, 3250.
the mAb had no significant effect on migration of LFA-12/2
lymphocytes into pLNs and spleen. VCAM-1 is another
ligand recognized by both a4b1 and a4b7 integrins (32, 33),
and in the present experiments, the anti–VCAM-1 mAb
MK2.7 completely eliminated homing of LFA-12/2 lym-
phocytes to pLNs and also substantially blocked entry into
both mLNs and PPs although not into spleen (Fig. 5).
Histochemical Evidence for Expression of VCAM-1 on LN
Endothelium. The foregoing experiments showed that
VCAM-1 has a role in the trafficking into LNs, suggesting
that this ligand is indeed expressed on the HEVs. To further
address this question, immunohistochemical staining was
performed using fresh frozen tissue sections of pLNs, mLNs,
and PPs from LFA-12/2 and LFA-11/1 mice and normal
C57BL/6 mice. In pLNs, anti–VCAM-1 mAb MK2.7
(IgG1) was identified to label the same HEVs as PNAd-
specific mAb MECA-79 (Fig. 7, a and b). Of interest was
the observation that the MAdCAM-1 mAb MECA-367
was negative, as was an IgG1 isotype control mAb, PyLT-1
(Fig. 7, c and d). In mLNs where both MAdCAM-1 and
PNAd are chiefly coexpressed on HEVs (34), VCAM-1 is also
present, whereas the isotype control mAb was negative (Fig. 7,
e–h). In a preliminary quantitative study of mLNs, complete
overlap was observed in HEV staining of VCAM-1 with one
other HEV ligand, MAdCAM-1 (data not shown). The level
of VCAM-1 expression was comparable on HEVs from all
LNs and from LFA-11/1, LFA-12/2, and C57BL/6 mice
(data not shown). Therefore the absence of LFA-1 did not in-
duce a compensatory increase in expression of VCAM-1.
To confirm that VCAM-1 is expressed on the luminal
surface of the endothelium and therefore accessible to re-
circulating lymphocytes, C57BL/6 mice were intrave-
nously injected for 10 min with rat anti–VCAM-1 mAb
MK2.7 or anti-HEV mAb MECA-325. On tissue sections
stained with anti–rat Ig, both the pLN and mLN HEVs
scored positive to a similar degree for both the anti–
VCAM-1 and the anti-HEV mAbs (data not shown). This
experiment provided a second type of histochemical proof
that VCAM-1 is luminally expressed on the HEVs of the LNs.
A Role for a4 Integrin–mediated Migration into Bone Marrow.
In the migration experiments with 51Cr-labeled lympho-
cytes, significantly fewer lymphocytes distributed into the
mouse carcass after treatment with a combination of LFA-1
and a4 mAbs (see Fig. 6). To discover the identity of the
relevant tissue compartment, individual body parts of mus-
cle, heart, kidney, thymus, and bone were isolated and
counted separately. The target tissue with diminished lym-
phocyte migration was determined to be the limb bones, in-
dicating that lymphocyte recirculation was occurring in the
bone marrow (data not shown). Within 1 h, a single femur
recruited z1% of 51Cr-labeled lymphocytes, suggesting that
the total bone marrow compartment attracted lymphocytes
at a rate comparable to the 5–10% lymphocyte entry into
the combined LNs. Which lymphocytes were migrating
into bone marrow was tested by using CT-labeled lympho-
cytes and subsequent staining with subset-specific mAbs de-1473 Berlin-Rufenach et al.
tected with Tricolor-conjugated anti–rat Ig. The ratio of
migrated to injected CD4/CD8/B220 subsets was z0.5/
1.0/2.0. This advantage for B cell and disadvantage for CD4
T cells were independent of LFA-1 expression status.
LFA-11/1 and LFA-12/2 cells did not significantly differ in
their trafficking to bone marrow (ratio of LFA-12/2 to LFA-
11/1 was 1.1; data not shown), suggesting that the migration
was not solely reliant on LFA-1. However, when LFA-12/2
lymphocytes were coinjected with a4 mAb, the trafficking to
bone marrow was completely abolished (Fig. 8). These results
suggest that migration into bone marrow can be accom-
plished either by LFA-1 or in its absence by an a4 integrin.
As the a4b7 mAb had a partial effect on migration, whereas
a4 mAb blocked migration completely, we conclude that in
bone marrow, in contrast to the migration into LNs, a4b1
dominates a4b7. Finally, the VCAM-1 mAb, but not MAd-
Figure 6. The effect of anti-a4
and LFA-1 mAbs on the migra-
tion of 51Cr-labeled BALB/c lym-
phocytes within 1 h after tail vein
injection into host BALB/c mice.
Distribution of radioactivity in
various organs when lymphocytes
were coinjected with anti-a4
mAb PS/2 (hatched bars), anti–
LFA-1 mAb H35.89.9 (cross-
hatched bars), anti–LFA-1 and a4
mAbs together (black bars), and
control (white bars). The a4 mAb
inhibited entry of lymphocytes
into PPs and intestine. The LFA-1
mAb inhibited entry of lympho-
cytes into pLNs and redistribution
to the spleen. The mAb combina-
tion inhibited entry of lympho-
cytes into pLNs, mLNs, PPs,
intestine, and the “body” and in-
creased redistribution into spleen.
Note the increased numerical scale
for the organs shown on the right.
Four animals were used per exper-
imental group (n 5 2; bars, 6SD).
Figure 5. The effect of vari-
ous mAbs on the homing of
LFA-1–deficient lymphocytes to
pLNs, mLNs, PPs, and spleen. In
each case, the relative ratio of
LFA-12/2 to LFA-11/1 migra-
tion (0.21, 0.51, 0.68, and 1.29,
respectively; see Fig. 3 b) is set at
100% in order to assess the fur-
ther reduction in migration
caused by specific antibodies.
Anti–a4 integrin (PS/2) blocked
the residual ability of LFA-12/2
lymphocytes to enter all three
LNs, but did not significantly af-
fect their entry into spleen. Anti-
a4b7 mAb DATK32 mirrored
the effects of a4 mAb on mLNs
and PPs, but reduced pLN mi-
gration to z25%. Anti–VCAM-1
mAb (MK2.7) eliminated the
migration of LFA-12/2 cells into
pLNs and partially limited their
entry into mLNs and PPs. Con-
versely, anti–MAdCAM-1 mAb
(MECA-367) blocked the hom-
ing of LFA-12/2 cells into PPs,
had a lesser effect on mLNs, and
showed no inhibition of lym-
phocyte entry into pLNs or
spleen. Four or five animals were
used per experimental group (n 5
2 or 3; bars, 6SD).1474 Role of LFA-1 and a4 Integrins in Lymphocyte Recirculation
CAM-1 mAb, had an inhibitory effect. Considered together,
these results demonstrate that migration of recirculating lym-
phocytes into bone marrow can be mediated by either LFA-1
or the a4 integrins, and, as in pLNs, that VCAM-1 serves as
the chief ligand for the latter receptors.
Discussion
This study shows that LFA-1 has a key role in migration to
the pLNs, other LNs, and bone marrow but not into the
spleen. Also revealed is a hitherto unrecognized ability of the
a4 integrins, a4b7 and a4b1, to compensate for the lack of
LFA-1 in lymphocyte trafficking to pLNs and other lymphoid
tissues, including bone marrow. In general, these findings
highlight common features between lymphocyte homing and
the response to inflammatory stimuli and extend the validity of
the multistep model of adhesion and transmigration.
The LFA-12/2 mouse described in this report has, as its key
phenotypic characteristic, pLNs that contain z30% normal
lymphocyte numbers, as also noted previously (25). The de-
creased trafficking of LFA-12/2 lymphocytes to the pLNs to
z20–30% of wild-type lymphocytes suggested that LFA-12/2
lymphocytes, irrespective of which subset, had difficulty
gaining entry to the LNs. This was confirmed by microscopic
studies showing that circulating LFA-12/2 lymphocytes
bound poorly to HEVs. Migration into mLNs and PPs was
also depressed, but LN cell counts were normal, suggesting
compensatory measures were in operation in these tissues
but not in pLNs. The decrease in migration of lymphocytes
to pLNs is consistent with previous work using function-
blocking LFA-1 mAbs (10) and has recently been reported in
another study using LFA-1–deficient mice (35). Thus, the
general importance of LFA-1 in mature lymphocyte traffick-
ing to secondary lymphoid tissue is confirmed.
In our studies, LFA-12/2 lymphocytes were able to gain
entry into the pLNs, albeit at a lower level, suggesting in-
volvement of further receptors. We here demonstrate these
additional receptors to be the a4 integrins. Skewed recep-
tor usage towards increased expression of a4 integrins in
LFA-12/2 mice as a possible cause of experimental bias was
excluded (data not shown). The fact that the presence of
mAbs to both LFA-1 and a4 integrins caused complete
blockade of lymphocyte entry into normal pLNs and other
LNs strongly implies that a4 has a critical role in migration
of normal lymphocytes into pLNs. That this role for a4 in-
tegrin has not previously been observed might be because
LFA-1 has a larger role than a4 integrin in adherence to
Figure 7. Histochemical demonstration of the presence of a4 integrin
ligands in LFA-11/1 pLNs (a–d) and mLNs (e–h). The panels show stain-
ing of identical tissue sections of HEVs in the pLNs with mAbs specific
for (a) VCAM-1, (b) PNAd, (c) MAdCAM-1, and (d) an isotype-
matched IgG1 control mAb and similarly, in the mLNs for (e) VCAM-1,
(f) PNAd, (g) MAdCAM-1, and (h) IgG1 control mAb. Original magnifi-
cation: a–h, 3150.
Figure 8. The effect of various mAbs on the relative entry of LFA-12/2
to LFA-11/1 lymphocytes into bone marrow. In the absence of antibody,
the relative ratio is 1.1. Coinjection of a4 mAb or VCAM-1 mAb com-
pletely inhibited the migration of LFA-12/2 cells, whereas a4b7 mAb has a
partial effect and MAdCAM-1 mAb is without effect.1475 Berlin-Rufenach et al.
pLN HEVs than HEVs of other organs. This is in good
agreement with intravital microscopy studies which show
LFA-1 and L-selectin are the essential codependent pLN-
specific adhesion pair for lymphocyte adherence to pLN
vessels (36). Put together, the data suggest that a4 integrins
have a less prominent role in adherence to pLN HEVs, but
potentially a larger role in the transmigration step.
Our data also suggest unexpectedly that a4b7 acts as the
major a4 receptor in conjunction with a4b1 in lympho-
cyte recirculation into pLNs. There has previously been no
evidence to link a4b7 with pLN migration, although its
dominant role in trafficking into mucosal tissue of the
mLNs and PPs is well documented (3, 17) and is confirmed
here. The integrin a4b1 has usually been associated with
inflammatory responses (18–20) rather than with lympho-
cyte recirculation. However, as these two a4 integrins might
be acting either in synergy or in sequence, the extent of the
contribution of a4b1 must await a potent murine CD29
blocking mAb. The results imply that the succession of ad-
hesive events in lymphocyte recirculation is similar to that
in inflammatory responses, and that the a4 integrins in co-
operation with L-selectin and LFA-1 have a more specific
and necessary role than previously perceived.
The data presented here identify VCAM-1 and not
MAdCAM-1 as ligand on pLN HEVs for a4 integrins in
spite of a4b7 involvement. The result was unexpected, as
a4b1 has been identified as the major VCAM-1 binding in-
tegrin in inflammatory responses (37) in studies using trans-
fectant (38) and cell lines (17). VCAM-1 also made a signifi-
cant contribution to trafficking into mLNs and, to a lesser
extent, PPs. This cooperative activity with MAdCAM-1 was
also unexpected, as it has previously been considered that en-
try into these LNs was regulated only by MAdCAM-1. The
findings presented here suggest that potential roles for a4b7
in addition to a4b1 should be sought in other circum-
stances where VCAM-1 is the major ligand.
One explanation for having overlooked the importance
of VCAM-1 as an HEV ligand is its reported absence from
normal lymphoid tissue (22, 23, 39), with the exception of
a report on its expression on rat HEVs (40). In the present
study, expression occurred at comparable levels on HEVs
in pLNs, mLNs, and PP LNs and without obvious differ-
ence between LFA-12/2 mice, their wild-type littermates,
C57BL/6, or BALB/c mice. Such broad and constant pres-
ence of VCAM-1 implies it is constitutively expressed
rather than as a consequence of an inflammatory signal or a
compensatory mechanism in LFA-12/2 mice.
The involvement of VCAM-1 raises the issue as to
whether lymphocytes can use this ligand for migration
across HEVs into the LN as well as adhesion to the luminal
surface of HEVs. In this study, the lack of LFA-1 decreased
migration across HEVs by z25% only, suggesting involve-
ment of other receptor/ligand pair(s) (data not shown). For
HUVECs, VCAM-1 is reported to be restricted to an api-
cal location and therefore available for adhesion but not for
transendothelial migration (41). However, monocytes can
transmigrate HUVECs, making use of a4/VCAM-1 inde-
pendently of b2 integrins (42). In mice, two major forms of
VCAM-1 have been identified, the common seven-domain
form and also a three-domain glycosylphosphatidylinositol
(GPI)-linked splice variant which is induced by inflamma-
tion (43, 44). It is of interest that in polarized epithelial cells,
the GPI-linked VCAM-1 was found apically, whereas the
seven-domain VCAM-1 was localized to the basolateral sur-
face, where it could theoretically serve as a ligand for trans-
migration (45). The issue of where VCAM-1 is expressed,
particularly in murine HEVs, warrants further investigation.
Migration of recirculating lymphocytes to bone marrow,
a primary lymphoid tissue, has been noted in the past (46).
Bone marrow serves as a site of hematopoiesis and for B
cell maturation in the mammal. It can also act as a reservoir
for a primary immune response in the absence of a spleen
and presence of L-selectin mAb (47). In this study, we find
an unexpectedly high degree of mature lymphocyte recir-
culation in which B cells dominate into bone marrow. We
suggest here that bone marrow, but not the thymus (data
not shown), should be considered as a major part of the
lymphocyte recirculation network.
Migration to bone marrow is restricted by adhesion
mechanisms. Both human (48) and murine (49) hemato-
poietic progenitors make use of a4 integrin to lodge in the
bone marrow. The a4 integrins are also reported to be
necessary for correct lymphocyte development (50). We
show that normal lymphocyte recirculation through the bone
marrow is regulated by LFA-1 and the a4 integrins and, in
contrast to the LNs, a4b1 substantially dominates a4b7. In
this context, it is again VCAM-1 and not MAdCAM-1
which acts as ligand for the a4 integrins. VCAM-1 is ex-
pressed constitutively by bone marrow sinusoidal vascula-
ture (51, 52), and as progenitor cells have been demon-
strated to roll on bone marrow endothelial VCAM-1 (48),
it can be speculated that other lymphocytes might behave
similarly. However VCAM-1 is also expressed constitu-
tively by stromal reticular cells (53, 54), and it is possible
that lymphocytes may be retarded not only at the level of
the endothelium but also within the bone marrow matrix.
Factors produced by the stromal cells might be beneficial
for the maintenance of the recirculating lymphocytes. For
example, the interaction with VCAM-1 might suppress
lymphocyte apoptosis (55). On the other hand, the incom-
ing cells might contribute to the regulation of hematopoiesis.
In summary, the observations presented here extend and
validate the concept of a multistage adhesion response requir-
ing selectins and integrins. Rather than exclusive LN-specific
use of receptors such as LFA-1 and L-selectin in trafficking to
pLNs or a4b7 to mucosal sites, we have presented evidence
that LFA-1 and the a4 integrins can operate in migration of
unstimulated lymphocytes to the pLNs as well as other sec-
ondary LNs and bone marrow. These general features, in-
cluding the use of VCAM-1 as an a4 integrin ligand, resem-
ble the response to an inflammatory signal. Our findings
suggest a unifying hypothesis for migration of lymphocytes
across HEVs into secondary lymphoid tissue and also establish
further parallels between the activities of adhesion receptors
in the “homing” context and the mechanisms used in the
more sporadic responses to tissue injury and inflammation.1476 Role of LFA-1 and a4 Integrins in Lymphocyte Recirculation
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